Kidney Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with Stage I kidney cancer (a specific early stage called T1N0M0) where the tumor is no larger than 8 cm, confirmed by MRI or CT scan
- You are willing to have at least one small gold marker (called a fiducial) placed in or near the tumor to help guide treatment
- You are 18 years of age or older
- You are generally well enough to carry out daily activities (a measure of overall health, confirm with trial site)
- You are expected to live for at least 12 more months
- You are able to have a CT and/or MRI scan (with or without contrast dye) within 120 days before joining the study
- You have not had any other cancer in the past 2 years, except for certain non-serious skin cancers
- Your blood test results meet specific levels for kidney function, blood clotting, and liver function (confirm exact values with trial site)
- You are willing and able to use reliable contraception during the study if you could become pregnant or father a child
- You are able to understand and sign a consent form agreeing to take part
Who may not be able to join:
- You have a permanent blood clotting disorder that would make placing the gold marker unsafe
- You have previously had radiation treatment to the upper abdomen area
- You have had another invasive cancer diagnosed within the last 2 years
- The gold markers cannot be clearly seen well enough to safely deliver the radiation treatment
- The radiation cannot be safely delivered without causing too much harm to nearby healthy tissue
- You are unable to have a contrast CT or MRI scan needed to plan your treatment
- Your platelet count is too low, or your blood does not clot properly, making it unsafe to place the gold marker through the skin
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Irving D Kaplan, MD, Beth Israel Deaconess Medical Center
Phone: 617-667-2345
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To determine the freedom from local tumor progression in patients treated with CyberKnife radiosurgery for primary renal tumors at 6 months
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.